Back to top

Tale of the Tape

Zacks Equity Research

Synthetic Biologics: 3 Reasons Why SYN Is a Top Choice for Momentum Investors
September 29, 2016

SYN

Trades from $3

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.

This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Synthetic Biologics Inc. (SYN - Free Report) as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for SYN’s status as a solid momentum stock below:

Short Term Price Change for Synthetic Biologics

A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.

With a one week price change of 6.16% compared to an industry average of -1.69%, SYN is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.

Fiscal Year EPS Estimate Changefor SYN

In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if SYN is poised to make a run based on fundamentals, or if the company is simply moving on speculation.

Over the past month, the full year earnings estimate for SYN has risen by 5.88%. On its own this is impressive, but consider that it also beats the industry average of 0.0% too. The trend is undeniably in Synthetic Biologics’ favor right now, and it suggests that the momentum might be long lasting for this stock.

SYN Earnings Estimate Revisions Moving in the Right Direction

While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with SYN as of late too.

Over the past two months, 3 earning estimate have gone higher compared to none lower for the full year, while we are also seeing that 3 estimates have moved upwards with no downward revisions for the next year time frame too. These revisions have helped to boost the consensus estimate as two months ago SYN was expected to post loss of 49 cents/share for the full year, though today it looks to have loss per share of 37 cents for the full year now, representing a solid increase which is something that should definitely be welcomed news to would-be investors.

SYNTHETIC BIOLG Price and Consensus

SYNTHETIC BIOLG Price and Consensus | SYNTHETIC BIOLG Quote

Bottom Line

Given these factors, investors shouldn’t be surprised to note that we have SYN as a security with a Zacks Rank #2 (Buy) and a Momentum Score of ‘B’.You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep SYN on your short list as this looks be a stock that is very well-positioned to soar in the near term.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

In-Depth Zacks Research for the Tickers Above

SYNTHETIC BIOLG (SYN) - FREE report >>